A PROMISING early-phase clinical trial has found that stapokibart, a monoclonal antibody targeting the IL-4 receptor alpha subunit, may offer a safe and effective treatment option for children aged 6–11 years with moderate-to-severe
Stapokibart Shows Promise for Atopic Dermatitis in Children
